2,745 Shares in AbbVie Inc. $ABBV Acquired by Tempo Wealth LLC

20 Jun 2026, 13:15 by Danessa Lincoln · The Markets Daily

Tempo Wealth LLC bought a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 2,745 shares of the company’s stock, valued at approximately $627,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ABBV. Chelsea Counsel Co. purchased a new stake in AbbVie in the third quarter valued at approximately $26,000. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie during the fourth quarter worth approximately $28,000. Westend Capital Management LLC purchased a new position in shares of AbbVie during the fourth quarter worth approximately $29,000. Imprint Wealth LLC increased its holdings in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares during the period. Finally, Texas Capital Bancshares Inc TX purchased a new stake in AbbVie in the 3rd quarter valued at $31,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 0.1%

NYSE ABBV opened at $216.63 on Friday. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $244.81. The stock has a market cap of $382.74 billion, a price-to-earnings ratio of 106.71, a price-to-earnings-growth ratio of 0.66 and a beta of 0.32. The business has a fifty day moving average of $212.18 and a 200-day moving average of $218.76.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business’s revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the business earned $2.46 earnings per share. As a group, analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 340.89%.

Analysts Set New Price Targets

Several brokerages have weighed in on ABBV. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Canaccord Genuity Group boosted their price target on AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $240.00 price objective on shares of AbbVie in a research note on Thursday, April 30th. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, June 7th. Finally, Evercore set a $235.00 target price on AbbVie in a report on Friday, May 15th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $253.43.

Check Out Our Latest Stock Report on ABBV

More AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie is reportedly close to buying Apogee Therapeutics for about $10.9 billion, a move that could strengthen its eczema and inflammatory-disease pipeline and support longer-term growth. AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
Positive Sentiment: AbbVie’s recent pipeline momentum, including SKINVIVE approval and promising CLL trial results, reinforces confidence in its R&D engine and diversification beyond core immunology drugs. AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
Neutral Sentiment: AbbVie announced a quarterly dividend of $1.73 per share, underscoring its strong cash generation and shareholder-return profile. AbbVie Declares Quarterly Dividend
Neutral Sentiment: AbbVie is also highlighting its oncology strategy at ASCO 2026, but this is more of a long-term strategic update than an immediate stock catalyst. ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology
Negative Sentiment: AbbVie’s shares had recently been under pressure as the market moved higher, reflecting some near-term investor caution before the acquisition news. AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
Negative Sentiment: AbbVie is facing ongoing litigation risk after HHS asked a court to dismiss its suit over drug-discount patients, which could create headline overhang. HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

About AbbVie

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.